Pulmonary outflow obstruction protects against heart failure in adults with congenitally corrected transposition of the great arteries by Helsen, Frederik et al.
	 1	
Citation Helsen F, De Meester P, Van Keer J, Gabriels C, Van De Bruaene A, 
Herijgers P, Rega F, Meyns B, Gewillig M, Troost E, Budts W. 
Pulmonary outflow obstruction protects against heart failure in adults 
with congenitally corrected transposition of the great arteries. Int J 
Cardiol. 2015 Oct 1;196:1-6. 
 
Archived version Author manuscript: the content is identical to the content of the 
published paper, but without the final typesetting by the publisher 
 
Published version http://linkinghub.elsevier.com/retrieve/pii/S0167-5273(15)01226-7 
 
Journal homepage http://www.internationaljournalofcardiology.com 
Author contact werner.budts@med.kuleuven.be 
+32 (0) 16 34 43 02 
IR https://lirias.kuleuven.be/handle/123456789/501680 
 
 
(article begins on next page) 
 
 
 
 
 
 
 
 
	 2	
Pulmonary Outflow Obstruction Protects Against Heart Failure in Adults with 
Congenitally Corrected Transposition of the Great Arteries 
Frederik Helsen a,b,1, Pieter De Meester a,b,1, Jan Van Keer b,1, Charlien Gabriels a,b,1, Alexander Van de 
Bruaene b,1, Paul Herijgers c,d,1, Filip Rega d,e,1, Bart Meyns d,e,1, Marc Gewillig f,g,1, Els Troost b,1, 
Werner Budts a,b,1,*  
 
a Division of Cardiology, Department of Cardiovascular Sciences, KU Leuven – University of 
Leuven, B-3000 Leuven, Belgium 
b Department of Cardiology, University Hospitals Leuven, B-3000 Leuven, Belgium 
c Division of Experimental Cardiac Surgery, Department of Cardiovascular Sciences, KU Leuven – 
University of Leuven, B-3000 Leuven, Belgium 
d Department of Cardiac Surgery, University Hospitals Leuven, B-3000 Leuven, Belgium 
e Division of Clinical Cardiac Surgery, Department of Cardiovascular Sciences, KU Leuven – 
University of Leuven, B-3000 Leuven, Belgium 
f Division of Cardiovascular Developmental Biology, Department of Cardiovascular Sciences, KU 
Leuven – University of Leuven, B-3000 Leuven, Belgium  
g Department of Paediatrics, University Hospitals Leuven, B-3000 Leuven, Belgium. 
 
1 This author takes responsibility for all aspects of the reliability and freedom from bias of the data 
presented and their discussed interpretation. 
* Corresponding author at: Adult Congenital Heart Disease, University Hospitals Leuven, Herestraat 
49, B-3000 Leuven, Belgium. E-mail address: werner.budts@uzleuven.be (W. Budts). 
 
This work was supported by the Agency for Innovation by Science and Technology (IWT, Flanders, 
Belgium) [101484] to PDM and [131025] to CG.  
The authors report no relationships that could be construed as a conflict of interest. 
 
Keywords: Congenital Heart Defects; Heart Failure; Survival; Transposition of Great Vessels; 
Tricuspid Valve Insufficiency 
	 3	
Abstract  
Background: Pulmonary outflow tract obstruction (POTO) reduces systemic atrioventricular valve 
(SAVV) regurgitation severity in congenitally corrected transposition of the great arteries (ccTGA). 
Therefore, pulmonary artery banding is proposed as a palliative intervention. We aimed to investigate 
the effect of native or surgically induced POTO on event-free survival, defined as the composite of 
all-cause mortality, heart transplantation, or congestive heart failure (CHF). 
Methods and Results: Patients with ccTGA (n=62; median age 27.5 (IQR 18.4-39.4) years; 39% with 
POTO) were selected from the Adult Congenital Heart Disease database of a tertiary hospital. At first 
visit, SAVV regurgitation ≥3/4, systemic RV dysfunction ≥moderate, and CHF were present in 26%, 
26%, and 15% of patients, respectively. Over a mean follow-up time of 10.1 ± 6.1 years, all-cause 
mortality, rate of heart transplantation, and CHF were 18%, 8% and 40%, respectively. SAVV 
regurgitation (HR: 1.99; 95% CI: 1.01-3.92; P = 0.048) and systemic RV dysfunction severity (HR: 
1.89; 95% CI: 1.05-3.37; P = 0.033) were associated with the composite endpoint, independently of 
age at baseline, POTO, Ebstein-like malformation, and systemic RV dilatation. Patients with POTO 
had lower risk for developing SAVV regurgitation ≥3/4 (HR: 0.18; 95% CI: 0.05-0.58; P = 0.004) and 
moderate systemic RV dysfunction (HR: 0.34; 95% CI: 0.15-0.78; P = 0.011). When POTO was 
present, the mean progression-free interval for the composite endpoint increased from 11.2 to 18.1 
years (P = 0.035). 
Conclusions: POTO is associated with an improved event-free survival in adults with ccTGA. 
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1. Introduction 
Congenitally corrected transposition of the great arteries (ccTGA) is characterized by atrioventricular 
and ventriculo-arterial discordance. This double discordance creates a situation where the blood is 
normally oxygenated, but the morphological right ventricle (RV) and the systemic atrioventricular 
valve (SAVV) are exposed to high, systemic pressures. In about 90% of patients this congenital 
malformation is associated with other cardiac lesions, mostly large ventricular septal defect (VSD), 
pulmonary valvular or subvalvular stenosis, or morphological abnormalities of the SAVV.[1-4] 
Patients with ccTGA frequently develop congestive heart failure (CHF).[5] The onset of CHF is 
driven by a vicious circle of pressure and volume overload on the systemic RV.  
However, until now the prime mover in the development of CHF has not been clearly defined. 
On the one hand, morphological abnormalities of the SAVV such as an Ebstein-like anomaly or a 
dysplasia could initiate a sequence leading to SAVV regurgitation, myocardial dysfunction and 
CHF.[2] In this hypothesis the volume overload from primary SAVV regurgitation is a ‘condicio sine 
qua non’. On the other hand, the continuous exposure to systemic pressure and a concordant coronary 
anatomy could initiate a sequence of compensatory systemic RV hypertrophy, abnormal RV 
myocardial perfusion, perfusion defects, and eventually myocardial dysfunction and CHF.[6, 7] 
SAVV regurgitation is then seen as the result of myocardial dysfunction and subsequent remodelling. 
The best way to avoid, or at least delay the onset of CHF in adults with ccTGA is also a matter of 
debate. Some authors suggest performing early SAVV surgery to preserve ventricular function.[8] 
Interestingly, interventions that increase subpulmonary left ventricle (LV) pressure load are associated 
with a reduction of SAVV regurgitation.[9-11] In addition, a favourable natural history of patients 
with the combination of VSD and pulmonary stenosis (PS) is noted.[12] In the 1980s a technique of 
retraining the subpulmonary LV by pulmonary artery banding before performing an arterial switch 
procedure was introduced in patients with systemic RV failure after Mustard and Senning 
procedures.[13] [14] Similarly, if the subpulmonary LV of a patient with ccTGA performs within a 
low resistance pulmonary circulation, it needs reconditioning by pulmonary artery banding before a 
double-switch procedure.[15] Recently, pulmonary artery banding has been performed as an open-end 
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palliation of patients with a systemic RV with good mid-term follow-up results.[16-18] However, 
there is a lack of data on long-term outcome.  
Therefore, the aim of this retrospective study was to investigate the proposed protective effect 
of pulmonary outflow tract obstruction (POTO) on event-free survival, defined as the composite of 
all-cause mortality, heart transplantation, or congestive heart failure (CHF). 
 
2. Methods 
2.1 Patient selection and data collection 
The records of all patients with isolated or complex ccTGA were retrieved from the Adult Congenital 
Heart Disease database of the University Hospitals Leuven, a tertiary care centre specialized in 
congenital heart disease. All files from January 1990 to January 2015 were retrospectively reviewed. 
Patients with a single ventricle, those who had undergone a double-switch operation, or those without 
at least one follow-up visit at our clinic were excluded. Baseline variables were documented at the 
first patient contact, defined as the moment of transfer out of paediatric care at the age of 16 – 18 
years, at first referral to the Adult Congenital Heart Disease clinic, or at the moment of the oldest 
retrievable echocardiographic exam if the patient follow-up started before 1990. For patient with 
SAVV prosthesis, the degree of SAVV regurgitation prior to valve replacement is reported. 
The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki. 
The local institutional review committee approved the study and waived informed consent.  
 
2.2 Echocardiographic data 
Comprehensive 2-dimensional echocardiographic examinations were performed and analysed in our 
institution by two senior cardiologists specialized in Adult Congenital Heart Disease (E.T. and W.B.). 
The SAVV was considered morphologically abnormal if there was evidence of structural 
abnormalities such as an Ebstein-like malformation, prolapse of valve leaflets, or dysplastic features. 
SAVV regurgitation severity was semiquantitatively assessed by Doppler colour flow mapping on the 
basis of size of the jet and reversal of flow in the pulmonary veins, and severity was graded on a scale 
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from 0 to 4.[19] Clinically important SAVV regurgitation was defined as SAVV regurgitation 
≥3/4.[2, 5] Systemic RV function and systemic RV dilatation were qualitatively assessed using an 
integrative multi-view approach, and impairment was graded on a scale from 0 to 3. Clinically 
important systemic RV dysfunction or dilatation was defined as at least moderate dysfunction or 
dilatation (≥2/3). POTO was defined as an instantaneous peak Doppler pressure gradient ≥30 mmHg 
in the subpulmonary LV outflow tract at rest. According to the pressure gradient, the patients were 
divided in 4 categories (<30 mmHg, 30-59 mmHg, 60-89 mmHg, and ≥90 mmHg).[20] The VSD size 
was estimated by echocardiography. The VSD was considered large if the defect size was associated 
with non-restrictive flow. All patients with a history of VSD, independent of VSD closure in 
childhood, were classified into the category (repaired) VSD.  
 
2.3 Endpoints 
Outcome analysis focused on the all-cause mortality, the need for heart transplantation, and the 
occurrence of CHF. CHF was diagnosed when the patient presented with the combination of relevant 
symptoms (i.e., New York Heart Association functional class III or IV), signs (i.e., elevated jugular 
venous pressure, hepatomegaly, pulmonary crackles, ankle swelling), an increase in cardiothoracic 
ratio compared to a previous chest X-ray, and evidence of fluid overload on echocardiography or 
elevated NT-proBNP levels. The development of SAVV regurgitation ≥3/4 and moderate systemic 
RV dysfunction was also reviewed. 
 
2.4 Statistical analysis 
Categorical variables are expressed as numbers and percentages. Continuous data are presented as 
mean ± SD or as median with interquartile range (IQR). Data were tested for normal distribution with 
the Shapiro-Wilk test. Differences between 2 groups for continuous variables were analysed using 
unpaired t-test or Wilcoxon-Mann-Whitney test, as appropriate; Fisher’s exact test was used for 
categorical variables. To quantify correlations between two variables, the Pearson correlation test or 
the point-biserial correlation test was used. For the purpose of statistical analysis, the degrees of 
SAVV regurgitation, systemic RV dysfunction and systemic RV dilatation were considered a 
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continuous variable. For time-to-event analyses, time 0 was defined as time of first documented visit 
to the Adult Congenital Heart Disease clinic. The time to the occurrence of a given event was 
documented in years, with censoring at the time of latest follow-up. Uni- and multivariate Cox 
regression analyses were performed to identify baseline characteristics associated with the 
development of the endpoints. Only those univariate variables with P<0.05 were subsequently entered 
into multivariate models. Hazard ratios (HRs) are presented with 95% confidence intervals (CIs). 
Kaplan-Meier analyses with log-rank testing were performed to assess the differences in event-free 
survival. 
All statistical tests were 2-sided, and a P-value <0.05 was considered statistically significant. 
Analyses were performed using IBM SPSS Statistics, version 20.  
 
3. Results 
3.1 Patient demographics and baseline characteristics 
The records of 70 patients with isolated or complex ccTGA were examined for eligibility. After 
reviewing all records, 62 patients were found eligible and included in the study. Patients were 
excluded for the following reasons: four had a single ventricle, one had undergone a double-switch 
operation, and three visited the Adult Congenital Heart Disease clinic just once.  
Table 1 summarizes baseline characteristics, both for the total patient cohort and for the 
patient groups with and without POTO. Median age at first presentation was 27.5 (IQR 18.4-39.4) 
years. The most frequent associated anomalies were (repaired) VSD, structural abnormal SAVV, and 
POTO. The reasons for POTO were native pulmonary valvular or subvalvular stenosis (71%), 
pulmonary artery banding (13%), and conduit or pulmonary homograft stenosis (17%). Of these 
patients, 7 had a gradient of 30-59 mmHg, 7 had a gradient of 60-89 mmHg, and 10 had a gradient of 
≥90 mmHg. The mean resting oxygen saturation in patients with a residual VSD was 93 ± 5 % (data 
from 1 patient is missing). Five patients with a residual VSD had resting oxygen saturation <90%, 
ranging from 79 to 89%. Clinically important SAVV regurgitation, systemic RV dysfunction, or RV 
dilatation were present in 26%, 26%, and 68% of patients, respectively. Figure 1 depicts the variation 
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in the degree of SAVV regurgitation depending on the presence or absence of POTO. Predefined CHF 
was present in 15%; the median age in this subgroup was 47.0 (IQR 20.3-56.1) years.  
 
3.2 Outcome 
Survival status was obtained of 57 (92%) patients. Mean follow-up time was 10.1 ± 6.1 years. The 
composite endpoint of death, heart transplantation, or CHF occurred in 40% of patients. All-cause 
mortality was 18% with a mean age of death of 52.2 ± 15.2 years, rate of heart transplantation was 8% 
with a mean age at transplantation of 32.2 ± 11.5 years, and 40% of patients were diagnosed with 
CHF with a mean age of 42.8 ± 15.8 years at diagnosis. Patients with a pressure gradient in the 
subpulmonary LV outflow tract of 30 to 59 mmHg experienced no clinical events. At latest follow-up, 
44% of patients had clinically important SAVV regurgitation and 57% had clinically important 
systemic RV dysfunction. Detailed results are listed in Table 2.  
 
3.3 Variables related with the composite endpoint of death, heart transplantation, or congestive heart 
failure 
On multivariate Cox regression analysis, the degrees of SAVV regurgitation (HR: 1.99; 95% CI: 
1.01-3.92; P = 0.048) and systemic RV dysfunction (HR: 1.89; 95% CI: 1.05-3.37; P = 0.033) were 
associated with the composite endpoint, independently of age at baseline, POTO, Ebstein-like 
malformation, and the degree of systemic RV dilatation. All risk factors examined are listed in Table 
3. 
There was a moderate positive relationship between the degrees of SAVV regurgitation and 
systemic RV dysfunction at baseline (r 0.31; P = 0.016). Because we found a strong negative 
relationship between the degrees of SAVV regurgitation and POTO (rpb -0.57; P <0.001), we decided 
to assess the relationship of SAVV regurgitation and systemic RV dysfunction in the group with and 
without POTO separately. The positive relationship between the degree of SAVV regurgitation and 
the degree of systemic RV dysfunction stayed present in the group without POTO, but it was 
completely absent in the group with POTO (r 0.36; P = 0.026 and r -0.68; P = 0.757, respectively). In 
order to better understand the mechanisms that have a positive or negative influence on the 
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development of clinically important SAVV regurgitation and systemic RV dysfunction, we performed 
further Cox regression analyses.  
 
3.4 Variables related with development of clinically important SAVV regurgitation 
Patients with POTO had lower risk of developing clinically important SAVV regurgitation (HR: 0.18; 
95% CI: 0.05-0.58; P = 0.004). The degrees of systemic RV dysfunction (HR: 1.59; 95% CI: 1.02-
2.46; P = 0.039), RV dilatation (HR: 1.95; 95% CI: 1.01-3.45; P = 0.022), and a residual large VSD 
(HR: 0.23; 95% CI: 0.06-0.99; P = 0.048) were also associated with the development of clinically 
important SAVV regurgitation.  
 
3.5 Variables related with development of clinically important systemic RV dysfunction 
Patients with POTO had lower risk of developing clinically important systemic RV dysfunction (HR: 
0.34; 95% CI: 0.15-0.78; P = 0.011). The degrees of SAVV regurgitation (HR: 1.77; 95% CI: 1.17-
2.66; P = 0.006), systemic RV dilatation (HR: 1.89; 95% CI: 1.13-3.18; P = 0.016), and residual large 
VSD (HR: 0.28; 95% CI: 0.10-0.80; P = 0.018) were also associated with the development of 
clinically important systemic RV dysfunction.  
 
3.6 Event-free survival analyses stratified for pulmonary outflow tract obstruction 
Mean progression-free survival for developing clinically important SAVV regurgitation or systemic 
RV dysfunction was significantly longer in the group with POTO than in the group without POTO 
(20.7 vs. 8.7 years; P = 0.001 and 16.3 vs. 6.5 years; P = 0.005, respectively). Moreover, mean 
progression-free survival for the composite endpoint of all-cause mortality, heart transplantation, or 
CHF was also significantly longer in the group with POTO than in the group without POTO (18.1 vs. 
11.2 years; P = 0.035). Figure 2 illustrates the Kaplan-Meier survival curves plotted according to 
POTO status. The influence of the different degrees of POTO on the composite endpoint is illustrated 
in Figure 3. When we consider the patients with POTO and a residual large VSD (13 patients) versus 
POTO without a residual large VSD (11 patients), there was no difference in the composite endpoint 
(mean progression-free survival 16.0 vs. 18.4 years; log-rank p=0.585).  
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4. Discussion 
In the present study, we showed that POTO was inversely correlated with the degree of SAVV 
regurgitation. Moreover, POTO was associated with a slower progression to clinically important 
SAVV regurgitation and systemic RV dysfunction, and an improved morbidity and mortality rate on 
long-term follow-up of adults with ccTGA. 
Congenitally corrected transposition of the great arteries is a congenital heart defect associated with 
important morbidity and mortality.[2, 4, 5, 21, 22] The relation between SAVV regurgitation, 
systemic RV dysfunction, and CHF is not completely understood.[4, 5, 23] In the study of Prieto et 
al.[2], clinically important SAVV regurgitation seemed to be responsible for the occurrence of CHF. 
However, in our study both SAVV regurgitation and systemic RV dysfunction were the main drivers 
of the composite endpoint of all-cause mortality, heart transplantation, or CHF. Prieto et al.[2] found, 
in patients followed from birth to early adulthood, that a morphological abnormal SAVV was the only 
factor associated with the development of clinically important SAVV regurgitation and that systemic 
RV dysfunction appeared almost always secondary to long-standing SAVV regurgitation. Our data 
seem to contradict these findings. By reviewing the data more into detail, Prieto et al.[2] did not take 
in account the presence of POTO, whereas in our study a substantial number of patients did have 
POTO. Moreover, our study indicates that POTO is inversely associated with the degree of SAVV 
regurgitation and provides evidence that POTO protects against clinically important SAVV 
regurgitation and systemic RV dysfunction. By delaying the onset of clinically important SAVV 
regurgitation and systemic RV dysfunction, POTO can postpone the onset of CHF, as proven by our 
data. 
Over the last decade, the congenital heart surgeons of our institution perform pulmonary 
artery (dilatable) banding on all asymptomatic patients when they are about 7 years old. Theoretically, 
POTO increases the afterload of the morphological LV, which counteracts the shift of the 
interventricular septum towards the morphological LV. This septal shift results in a less spherical 
systemic RV, a less distorted subvalvular SAVV complex, and a reduced SAVV regurgitation 
	 11	
severity.[10] As a consequence, by avoiding volume overload from the SAVV regurgitation, the 
systemic RV is longer exposed to an isolated systemic pressure load. This could explain why we 
found that clinically important SAVV regurgitation, systemic RV dysfunction, and the composite 
endpoint occurred significantly later in this subset of patients. Considering the results of our study, 
pulmonary artery banding could gain importance over the following years.  
 
5. Limitations 
This study has some limitations. First, this was a retrospective, single-institution cohort study with a 
limited number of patients. Secondly, the study was designed to evaluate outcomes of patients with 
ccTGA visiting the Adult Congenital Heart Disease clinic. Some patients were directly transferred 
from Paediatric Cardiology to the Adult Congenital Heart Disease clinic, others were referred at later 
age. At inclusion, a considerable number had systemic RV dysfunction, SAVV regurgitation, and 
some were already suffering from CHF episodes. However, this heterogeneity reflects well the patient 
population that is seen by adult congenital heart specialists. Thirdly, echocardiographic assessment of 
RV function was mostly qualitative. Metrics of longitudinal RV shortening were available in some 
patients, however the contraction pattern of the systemic RV is predominately circumferential and 
radial.[24, 25] Qualitative estimation of systemic RV function correlates relatively well with cardiac 
MRI-derived EF, although the best results are found in comparisons between mild and severe 
impairment.[26] To minimize interobserver variability, all assessments of ventricular function were 
done by two expert readers. Fourthly, the diagnosis of CHF is difficult in patients with a systemic RV 
and the value of BNP and NT-proBNP unclear in this population.[27] Therefore, we relied on the 
clinical judgement of the treating congenital cardiologist. Last, patients numbers in the different 
categories of POTO are limited, thus the results presented in Figure 3 are merely hypothesis 
generating. 
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6. Conclusions 
In conclusion, POTO is a protective factor in patients with ccTGA. It is associated with a slower 
progression of SAVV regurgitation and systemic RV dysfunction, thus delaying morbidity and 
mortality. Furthermore, these results feed the hypothesis that pulmonary artery banding can be a 
palliative intervention in patients without POTO.   
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Table 1. Demographic and clinical variables at inclusion 
Baseline variable Total population 
(n=62) 
POTO absent 
(n=38) 
POTO present 
(n=24) 
P-value 
Age at first visit, median (IQR), y 27.5 (18.4-39.4) 28.0 (19.3-40.1) 25.2 (18.0-36.2) 0.452 
Female gender, n (%) 18 (29) 10 (26) 8 (33) 0.578 
Associated anomalies, n (%)     
(Repaired) VSD 36 (58) 13 (34) 23 (96) <0.001* 
(Repaired) large VSD 32 (52) 11 (29) 21 (88) <0.001* 
Residual VSD 19 (31) 4 (11) 15 (63) <0.001* 
Residual large VSD 16 (26) 3 (8) 13 (54) <0.001* 
POTO 24 (39)    
Morphologic abnormal SAVV 34 (55) 19 (50) 15 (63) 0.434 
Ebstein-like malformation 20 (32) 12 (32) 8 (33) >0.999 
Pacemaker, n (%) 9 (15) 7 (18) 2 (8) 0.462 
Previous OHS, n (%) 23 (37) 12 (32) 11 (46) 0.291 
Previous CHF episode, n (%) 9 (15) 8 (21) 1 (4) 0.135 
NYHA functional class, I/II/III/IV, n 41/16/5/0 25/9/4/0 16/7/1/0 0.634 
Residual large VSD absent 32/9/5/0 24/7/4/0 8/2/1/0  
Residual large VSD present 9/7/0/0 1/2/0/0 8/5/0/0  
Presence of CHF signs, n (%) 4 (7) 4 (11) 0 (0) <0.001* 
Residual large VSD absent 4 (9) 4 (11) 0 (0)  
Residual large VSD present 0 (0) 0 (0) 0 (0)  
SAVV regurgitation      
≥3/4, n (%) 16 (26) 16 (42) 0 (0) <0.001* 
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Degree, median (IQR) 2 (1.5-3) 2.5 (2-3) 1.5 (1-2) <0.001* 
Systemic RV Dysfunction     
≥Moderate, n (%) 16 (26) 12 (32) 4 (17) 0.242 
Degree, median (IQR), /3 1 (0-2) 1 (0.5-2) 0.5 (0-1) 0.048* 
Systemic RV Dilatation      
≥Moderate, n (%) 42 (68) 28 (74) 14 (58) 0.268 
Degree, median (IQR), /3 2 (1-2) 2 (1-2) 2 (1-2) 0.094 
CHF, congestive heart failure; IQR, interquartile range; n, number of patients; OHS, open heart 
surgery; POTO, pulmonary outflow tract obstruction; RV, right ventricular; SAVV, systemic 
atrioventricular valve; VSD, ventricular septal defect; y, years. 
*Statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 18	
Table 2. Outcome 
 Total population (n=62) 
Follow-up time, mean ± SD, y 
          median (IQR) 
10.1 ± 6.1 
10.0 (5.0-15.3) 
All-cause mortality, n (%) 11 (18) 
CV mortality, n/all-cause 
mortality (%) 
7 (64) 
HTx, n (%) 5 (8) 
CHF, n (%) 25 (40) 
Composite of all-cause 
mortality, HTx, or CHF, n (%) 
25 (40) 
SAVV regurgitation ≥3/4 at 
last follow-up, n (%) 
27 (44) 
Moderate systemic RV 
dysfunction at last follow-up, 
n(%) 
35 (57) 
 
CV, cardiovascular; CHF, congestive heart failure; HTx, heart transplantation; IQR, interquartile 
range; n, number of patients; RV, right ventricular; SAVV, systemic atrioventricular valve; SD, 
standard deviation; y, years. 
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Table 3. Baseline variables related with the composite endpoint of death, heart transplantation, 
or congestive heart failure 
Variable Univariate analyses Multivariate analysis 
HR 95 % CI P-value HR 95 % CI P-value 
Age at first visit 1.05 1.02-1.08 0.001* 1.03 0.99-1.07 0.069 
Female gender 0.63 0.23-1.69 0.361    
Associated anomalies       
   (Repaired) VSD 0.71 0.31-1.60 0.408    
   (Repaired) Large VSD 0.83 0.37-1.86 0.651    
   Residual large VSD 0.92 0.38-2.21 0.844    
   Pulmonary outflow obstruction  0.38 0.15-0.98 0.046* 0.75 0.22-2.52 0.640 
   Morphologic abnormal SAVV 0.88 0.40-1.95 0.760    
Ebstein-like malformation 0.33 0.11-0.96 0.042* 0.38 0.10-1.42 0.150 
Previous OHS 1.25 0.56-2.80 0.582    
Pacemaker 1.54 0.58-4.13 0.387    
Degree of SAVV regurgitation 2.13 1.33-3.41 0.002* 1.99 1.01-3.92 0.048* 
Degree of systemic RV dysfunction 2.18 1.40-3.38 0.001* 1.89 1.05-3.37 0.033* 
Degree of systemic RV dilatation  1.87 1.01-3.48 0.047* 1.01 0.55-1.82 0.985 
 
CI, confidence interval; HR, hazard ratio; n, number of patients; OHS, open heart surgery; RV, right 
ventricular; SAVV, systemic atrioventricular valve; VSD, ventricular septal defect. 
*Statistically significant. 
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Figure 1. Boxplot of the degree of SAVV regurgitation for patients with or without pulmonary 
outflow tract obstruction.  
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Figure 2. Kaplan-Meier estimates for event-free survival, i.e. SAVV regurgitation ≥3/4 (A), moderate 
systemic RV dysfunction (B), and the composite endpoint of death, heart transplantation, or CHF (C). 
Comparison according to the presence or absence of pulmonary outflow tract obstruction at baseline. 
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Figure 3.  Kaplan-Meier estimates for the composite endpoint of death, heart transplantation, or CHF. 
Comparison according to the degree of pulmonary outflow tract obstruction at baseline. 
 
